

ACORDA THERAPEUTICS INC  
Form 8-K  
August 25, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): August 24, 2015**

**Acorda Therapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation)**

**000-50513**  
**(Commission**  
**File Number)**

**13-3831168**  
**(I.R.S. Employer**  
**Identification No.)**

**420 Saw Mill River Road,**

**10502**

**Ardley, NY**

**(Address of principal executive offices)**

**(Zip Code)**

**Registrant's telephone number, including area code: (914) 347-4300**

**Not Applicable**

**Former name or former address, if changed since last report**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On August 24, 2015, Acorda Therapeutics, Inc. (the Company ) issued a press release announcing that the United States Patent and Trademark Office Patent Trials and Appeals Board will not institute inter partes review of U.S. Patent Nos. 8,663,685 and 8,007,826. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated by reference into this Item.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

*Exhibit*

<i>No.</i>	<i>Description</i>
99.1	Press Release dated August 24, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Acorda Therapeutics, Inc.**

August 25, 2015

By: /s/ Michael Rogers  
Name: Michael Rogers  
Title: Chief Financial Officer

**EXHIBIT INDEX**

<i>Exhibit No.</i>	<i>Description</i>
99.1	Press Release dated August 24, 2015